Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results

Rhea-AI Summary

Senseonics (NASDAQ: SENS) reported second quarter 2026 revenue of $14.5 million, up approximately 120% year-over-year, with U.S. revenue of $12.6 million growing more than 150%. Gross margin improved to about 59%, versus 47% a year earlier.

Net loss widened to $36.7 million, or $0.63 per share, compared to a $14.5 million loss, or $0.36 per share, in Q2 2025, driven by higher R&D and SG&A expenses related to Gemini and Freedom development and commercial integration. Cash, restricted cash and short-term investments totaled about $143 million at June 30, 2026, with long-term debt of roughly $55.8 million.

According to Senseonics, full-year 2026 revenue guidance was raised to $62–$66 million and gross margin guidance to 58–61%. The company completed the transition of European Eversense commercialization in-house and expanded its Eon Care nursing network to over 90 nurses, now handling around 40% of insertion procedures.

Positive

• Q2 2026 revenue $14.5 million, up ~120% year-over-year
• U.S. revenue $12.6 million, growth of more than 150% year-over-year
• Gross margin expanded to ~59% from 47% in Q2 2025
• 2026 revenue guidance raised to $62–$66 million, implying 76–87% growth
• 2026 gross margin guidance increased to 58–61% from 55–58%
• Liquidity about $143 million in cash, restricted cash and short-term investments after raising over $100 million in Q2

Negative

• Net loss widened to $36.7 million from $14.5 million year-over-year
• SG&A expenses rose to $32.9 million from $9.7 million in Q2 2025
• R&D expenses increased to $11.6 million from $7.7 million year-over-year
• Shares outstanding grew to 52.9 million from 41.3 million, indicating dilution
• Long-term debt increased to about $55.8 million from $35.6 million

News Explained

The Q2 financing included approximately $90 million of equity proceeds, and common shares outstanding were 52,864,750 at June 30, 2026, versus 41,265,778 at December 31, 2025. Issuing shares increases the share count and reduces an existing holder’s percentage ownership absent offsetting changes, while the Hercules facility is described as up to $140 million rather than as a stated amount drawn.

Market reaction after 2Q26 earnings report: SENS +6.21%

+6.21% $5.47

15m delay

+6.21% Vs previous close

$5.47 Last Price

$5.11 $5.70 Day Range

$285.55M Market Cap

1.2x Rel. Volume

Following this news, SENS has gained 6.21%, reflecting a notable positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $5.47.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The stock is up +8.0% following this news. Historical earnings reactions included -6.16% after Q1 20...

Analysis

The stock is up +8.0% following this news. Historical earnings reactions included -6.16% after Q1 2026 results. A strong positive scenario would differ from that tag-matched precedent; current data also showed moderate short positioning, a volatility consideration.

Key Figures

Q2 Revenue: $14.5 million Full-Year Revenue Guidance: $62 million to $66 million Full-Year Revenue Growth: 76% to 87% +5 more

8 metrics

Q2 Revenue $14.5 million Q2 2026; approximately 120% year-over-year increase

Full-Year Revenue Guidance $62 million to $66 million FY 2026; raised from $60 million to $64 million

Full-Year Revenue Growth 76% to 87% FY 2026 outlook

Q2 Gross Margin approximately 59% Q2 2026; compared with 47% in Q2 2025

Full-Year Gross Margin Guidance 58% to 61% FY 2026; raised from 55% to 58%

Net Loss $36.7 million, or $0.63 loss per share Q2 2026; compared with $14.5 million or $0.36 per share in Q2 2025

Cash and Restricted Cash $143.0 million As of June 30, 2026

Outstanding Indebtedness $55.5 million As of June 30, 2026, including accrued interest

Previous Earnings Reports

5 past events · Latest: May 07 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 07	1Q26 earnings	Positive	-6.2%	Revenue grew 87% and guidance increased after equity and debt financing.
Mar 02	4Q25 earnings	Positive	-18.1%	Revenue increased, Eversense 365 received CE Mark, and Gemini enrollment began.
Nov 05	3Q25 earnings	Positive	-7.6%	Revenue grew 90%, gross profit improved, and net loss narrowed year-over-year.
Aug 06	2Q25 earnings	Positive	-4.9%	Revenue grew 37% and the company raised $77.8 million in gross proceeds.
May 08	1Q25 earnings	Positive	-15.2%	Revenue grew 24%, gross profit improved, and net loss decreased year-over-year.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Senseonics' tag-matched earnings announcements all produced negative 24-hour price reactions despite generally positive operating updates.

Key Terms

continuous glucose monitoring, automated insulin delivery system, tetracycline class

3 terms

continuous glucose monitoring medical

"medical technology company focused on ... implantable continuous glucose monitoring (CGM) systems"

Continuous glucose monitoring is a system that tracks blood sugar levels in real-time throughout the day and night. It provides constant updates, similar to a car's dashboard showing speed and fuel level at all times. For investors, advancements in this technology can signal progress in health monitoring devices, which may influence the growth and valuation of companies in the healthcare sector.

automated insulin delivery system medical

"Eversense 365 in combination with the twiist Automated Insulin Delivery system"

An automated insulin delivery system is a device that automatically monitors blood sugar levels and adjusts insulin delivery without needing manual input. Think of it as a smart thermostat that keeps a room’s temperature just right, ensuring stable levels. For investors, such systems represent advances in healthcare technology that can improve quality of life and potentially reduce long-term medical costs.

tetracycline class medical

"or when taking medications of the tetracycline class"

A group of antibiotics that share a common chemical structure and work by blocking bacteria from making proteins they need to grow. Think of them as a family of tools designed to stop many kinds of bacterial infections; some are older, well-known medicines and others are newer derivatives that aim to overcome resistance. Investors follow this class because regulatory approvals, patent status, clinical trial results, and bacterial resistance trends directly affect the commercial value of drugs in development or on the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-year
• Raising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%
• Achieved gross margin of approximately 59% during Q2, and raising full-year gross margin guidance to a range of 58% to 61% from 55% to 58%
  
  

GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced second quarter 2026 financial results and provided a business update.

Recent Highlights & Accomplishments

• Drove second consecutive quarter of strong execution and performance since bringing U.S. Eversense® commercial operations in-house, delivering expansion of second quarter revenue to $14.5 million and gross margins to approximately 59%
• Continued robust U.S. commercial momentum, with U.S. revenue growing more than 150% year-over-year, our highest quarterly shipment volume in company history, and active prescribers up approximately 130% year-over-year
• Scaled Eon Care past 90 nurses and to approximately 40% of Eversense insertion procedures, on track for our year-end goal of 100 nurses
• Closed the commercial transition of the European business from Ascensia in June, bringing the full sales and marketing organization in-house across Germany, Italy, Spain and Sweden
• Strengthened the balance sheet with the more than $100 million raised during Q2 — approximately $90 million in equity proceeds plus an expanded Hercules Capital facility of up to $140 million
  
  

“This was the strongest quarter in Senseonics’ history, achieving record revenue and expanded margins, while integrating European commercial operations, building Eon Care, and advancing our Gemini and Freedom development programs,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “Revenue grew approximately 120% year-over-year, and we delivered gross margin above our guided range for the second consecutive quarter, which validates the decision we made to bring our commercial organization fully in-house. The European commercial CGM organization is now integrated into Senseonics, and Eon Care continues to scale as one of our most important growth drivers. Given our momentum, we’re raising our full-year revenue and margin guidance. We’re not just growing the business — we’re redefining what a CGM can be.”

“Our commercial momentum continues to build, with strong U.S. direct-to-consumer results, now representing our largest source of new patients, improved productivity across our health care provider channel, and continued expansion of Eon Care,” added Brian Hansen, Chief Commercial Officer of Senseonics. “We were also encouraged by continued uptake of Eversense 365 in combination with the twiist Automated Insulin Delivery system. We look forward to continuing to drive performance with Eversense global commercialization now fully under Senseonics control.”

Second Quarter 2026 Results:

Total revenue for the second quarter of 2026 was $14.5 million, an increase of approximately 120% compared to $6.6 million for the second quarter of 2025. U.S. revenue was $12.6 million for the second quarter of 2026, an increase of more than 150% compared to $4.9 million for the second quarter of 2025, and revenue outside the U.S. was $1.9 million compared to $1.7 million in the prior year period, an increase of approximately 12%, reflecting the timing of tender updates in Europe as the Company continued its commercial transition from Ascensia. The Company expects this timing dynamic to normalize in the third and fourth quarters, with Europe still expected to represent approximately 20% of full-year revenue.

Second quarter 2026 gross profit was $8.6 million, representing gross margin of approximately 59%, compared to gross profit of $3.1 million, or 47% gross margin, for the second quarter of 2025.

Second quarter 2026 research and development expenses were $11.6 million, compared to $7.7 million for the second quarter of 2025, reflecting Gemini clinical and ongoing development of Freedom.

Second quarter 2026 selling, general and administrative expenses were $32.9 million, compared to $9.7 million for the second quarter of 2025, related primarily to the commercial integration and European transition.

Net loss was $36.7 million, or $0.63 loss per share, in the second quarter of 2026 compared to net loss of $14.5 million, or $0.36 loss per share, in the second quarter of 2025.

As of June 30, 2026, cash, restricted cash, and cash equivalents totaled $143.0 million, and outstanding indebtedness, including accrued interest, was $55.5 million, reflecting the more than $100 million raised in the second quarter through the equity offering and the amended Hercules Capital credit facility.

Full Year 2026 Financial Outlook

Senseonics is raising its full-year 2026 global net revenue guidance to $62 million to $66 million from $60 million to $64 million, representing year-over-year growth of 76% to 87%, and is raising its full-year gross margin guidance to a range of 58% to 61% from its prior range of 55% to 58%. The Company’s outlook continues to reflect the ongoing roll-out of Eversense 365 outside the United States, planned direct-to-consumer marketing investment, the status of other sales and marketing initiatives, and utilization of the patient assistance programs for Eversense 365.

Conference Call Information

Management will hold a conference call to review the Company’s second quarter 2026 performance starting today at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics’ website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-343-5172 (US/Canada) or 1-203-518-9856 (International), passcode SENSQ2, approximately five to ten minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the design, development and commercialization of glucose monitoring products to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense^® 365 and Eversense^® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

About Eversense

The Eversense Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and up to 180 days for Eversense E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense 365 and one time per day after day 21 for Eversense E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue and gross margin guidance under the heading “Full Year 2026 Financial Outlook,” statements regarding the performance of Senseonics and/or Eversense, the expected normalization of European revenue timing dynamics and Europe representing approximately 20% of full-year revenue, the anticipated achievement of our 100-nurse Eon Care year-end goal, the ongoing commercial transition and roll-out of Eversense 365 in Europe, including the timing of tender updates, the expanded compatibility of Eversense 365 with automated insulin delivery systems, the future demand for Eversense, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties related to the continued commercial transition and roll-out of Eversense 365 in the European Union, including the timing of tender updates; risks related to the pace of Eon hiring and network scaling; uncertainties in insurer, regulatory and administrative processes and decisions; uncertainties in finalizing integration and commercial terms and coordination with health systems and other collaboration partners and third parties; uncertainties inherent in the ongoing commercialization and expansion of the Eversense product and Senseonics’ and its partners’ activities; uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs; the Company’s ability to satisfy conditions for future borrowings under the Hercules facility; and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2025 and quarterly reports on Form 10-Q filed with the SEC under the heading “Risk Factors.” The forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

Senseonics Investor Contact

Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

Senseonics Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data)
	June 30,				December 31,
	2026				2025
		(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	44,753			$	40,234
Restricted cash		315				315
Short term investments, net		97,906				53,796
Accounts receivable, net		9,137				6,807
Accounts receivable, net - related parties		1,132				5,312
Inventory, net		8,458				6,703
Prepaid expenses and other current assets		4,755				4,366
Total current assets		166,456				117,533
Deposits and other assets		6,059				4,536
Property, equipment and intangible assets, net		4,320				4,200
Total assets	$	176,835			$	126,269
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	4,824			$	4,059
Accrued expenses and other current liabilities		16,032				15,091
Accrued expenses and other current liabilities, related parties		3,823				5,198
Total current liabilities		24,679				24,348
Long-term debt and notes payables, net		55,808				35,586
Non-current operating lease liabilities		6,035				5,289
Total liabilities		86,522				65,223
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value per share; 140,000,000 and 70,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 52,864,750 shares and 41,265,778 shares issued and outstanding as of June 30, 2026 and December 31, 2025		53				41
Additional paid-in capital		1,176,339				1,077,923
Accumulated other comprehensive income		(54	)			69
Accumulated deficit		(1,086,025	)			(1,016,987	)
Total stockholders’ equity		90,313				61,046
Total liabilities and stockholders’ equity	$	176,835			$	126,269

Senseonics Holdings, Inc. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data)
	Three Months Ended								Six Months Ended
	June 30,								June 30,
	2026				2025				2026				2025
Revenue, net	$	12,675			$	3,223			$	22,016			$	5,033
Revenue, net - related parties		1,808				3,426				4,178				7,873
Total revenue		14,483				6,649				26,194				12,906
Cost of sales		5,924				3,528				10,695				8,280
Gross profit		8,559				3,121				15,499				4,626
Expenses:
Research and development expenses		11,639				7,715				20,250				15,014
Selling, general and administrative expenses		32,908				9,729				63,083				17,423
Operating loss		(35,988	)			(14,323	)			(67,834	)			(27,811	)
Other income (expense), net:
Interest income		1,032				973				1,774				1,648
Interest expense		(1,600	)			(1,145	)			(2,792	)			(2,574	)
Other expense		(149	)			(6	)			(186	)			(23	)
Total other income (expense), net		(717	)			(178	)			(1,204	)			(949	)
Net Loss		(36,705	)			(14,501	)			(69,038	)			(28,760	)
Other comprehensive loss
Unrealized (loss) gain on marketable securities		(62	)			26				(123	)			23
Other comprehensive (loss) gain		(62	)			26				(123	)			23
Total comprehensive loss	$	(36,767	)		$	(14,475	)		$	(69,161	)		$	(28,737	)
Basic net loss per common share	$	(0.63	)		$	(0.36	)		$	(1.33	)		$	(0.75	)
Basic weighted-average shares outstanding		57,842,713				40,668,245				51,910,006				38,319,113
Diluted net loss per common share	$	(0.63	)		$	(0.36	)		$	(1.33	)		$	(0.75	)
Diluted weighted-average shares outstanding		57,842,713				40,668,245				51,910,006				38,319,113

FAQ

How did Senseonics (SENS) perform in Q2 2026?

Senseonics reported Q2 2026 revenue of about $14.5 million, up roughly 120% year-over-year. According to Senseonics, U.S. revenue reached $12.6 million and gross margin improved to approximately 59%, while net loss widened to $36.7 million on higher operating expenses.

Did Senseonics (SENS) raise its 2026 revenue guidance after Q2 2026 results?

Yes, Senseonics raised its 2026 revenue guidance to $62–$66 million, from $60–$64 million. According to Senseonics, this range represents expected year-over-year growth of 76% to 87% and reflects ongoing Eversense 365 rollout and planned commercial investments.

What was Senseonics’ gross margin in Q2 2026 and new margin guidance?

Senseonics reported Q2 2026 gross margin of about 59%, up from 47% a year earlier. According to Senseonics, full-year 2026 gross margin guidance was increased to a range of 58–61%, compared with the prior outlook of 55–58%.

What was Senseonics’ net loss and EPS for Q2 2026?

Senseonics recorded a Q2 2026 net loss of $36.7 million, or $0.63 per share. According to Senseonics, this compares with a net loss of $14.5 million, or $0.36 per share, in Q2 2025, reflecting higher R&D and SG&A spending.

How strong is Senseonics’ balance sheet after Q2 2026?

At June 30, 2026, Senseonics held about $143 million in cash, restricted cash and short-term investments. According to Senseonics, long-term debt was roughly $55.8 million, following more than $100 million raised in Q2, including equity and an expanded Hercules Capital facility.

What operational milestones did Senseonics (SENS) highlight in Q2 2026?

Senseonics completed the transition of European Eversense commercialization in-house and scaled its Eon Care network to over 90 nurses. According to Senseonics, Eon Care conducted around 40% of Eversense insertion procedures and the company reported its highest quarterly shipment volume.

How did international revenue trend for Senseonics in Q2 2026?

International revenue was about $1.9 million in Q2 2026, up roughly 12% year-over-year. According to Senseonics, European results reflected timing of tender updates during the commercial transition, with Europe still expected to represent around 20% of full-year 2026 revenue.